Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]

M Reck; T-E Ciuleanu; M Cobo; M Schenker; B Zurawski; J Menezes; E Richardet; J Bennouna; E Felip; O Juan-Vidal; A Alexandru; H Sakai; A Lingua; F Reyes; P-J Souquet; P De Marchi; C Martin; M Pérol; A Scherpereel; S Lu; L Paz-Ares; D P Carbone; A Memaj; S Marimuthu; X Zhang; P Tran; T John

doi:10.1016/j.esmoop.2021.100345

Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]

ESMO Open. 2021 Dec;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 2.

Authors

M Reck¹, T-E Ciuleanu², M Cobo³, M Schenker⁴, B Zurawski⁵, J Menezes⁶, E Richardet⁷, J Bennouna⁸, E Felip⁹, O Juan-Vidal¹⁰, A Alexandru¹¹, H Sakai¹², A Lingua¹³, F Reyes¹⁴, P-J Souquet¹⁵, P De Marchi¹⁶, C Martin¹⁷, M Pérol¹⁸, A Scherpereel¹⁹, S Lu²⁰, L Paz-Ares²¹, D P Carbone²², A Memaj²³, S Marimuthu²³, X Zhang²³, P Tran²³, T John²⁴

Affiliations

¹ Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. Electronic address: m.reck@lungenclinic.de.
² Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania.
³ Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
⁴ Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania.
⁵ Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland.
⁶ Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.
⁷ Department of Clinical Oncology, Instituto Oncológico de Córdoba, Córdoba, Argentina.
⁸ Department of Thoracic Oncology, University Hospital of Nantes and INSERM, CRCINA, Nantes, France.
⁹ Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
¹⁰ Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain.
¹¹ Department of Oncology, Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania.
¹² Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
¹³ Department of Medical Oncology, Instituto Medico Rio Cuarto, SA, Córdoba, Argentina.
¹⁴ Department of Medical Oncology, Fundación Arturo López Pérez, Santiago, Metropolitana, Chile.
¹⁵ Department of Pneumology, Hôpital Lyon Sud, Lyon, Pierre Bénite, France.
¹⁶ Department of Oncology, Barretos Cancer Hospital, Barretos, Brazil.
¹⁷ Department of Thoracic Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
¹⁸ Department of Thoracic Oncology, Léon Bérard Cancer Center, Lyon, France.
¹⁹ Department of Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France.
²⁰ Department of Medical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China.
²¹ Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit, Universidad Complutense & CiberOnc, Madrid, Spain.
²² Department of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, USA.
²³ Bristol Myers Squibb, Princeton, USA.
²⁴ Department of Medical Oncology, Austin Hospital, Heidelberg, Australia.

No abstract available

Publication types

Published Erratum